Premature Ovarian Insufficiency: Long-Term Health Consequences and Hormone Replacement Therapy Strategies
https://doi.org/10.31550/1727-2378-2023-22-5-49-53
Abstract
Aim: analysis of modern views on the pathogenesis of complications and long-term consequences of sex hormone deficiency among patients with premature ovarian insufficiency (POI), as well as the possibilities and strategies of hormone replacement therapy (HRT) for their treatment and prevention.
Key Points. The consequences of a sex hormones deficiency in women with POI are not only short-term clinical manifestations similar to menopause, but also long-term negative outcomes for general health and life. HRT has therapeutic and prophylactic potential for all clinical aspects of the disease. However, the currently developed standard therapeutic strategies do not always allow to completely stop the symptoms of POI and ensure reliable prevention of complications in the future.
Conclusion. The choice of adequate doses and composition of HRT, along with an interdisciplinary approach to the treatment of this pathology, will make it possible to level the associated risks and ensure a high quality of life for patients.
Keywords
premature ovarian insufficiency,
hormone replacement therapy,
cardiovascular diseases,
osteoporosis,
genitourinary menopausal syndrome
Supporting agencies: The authors declare that there is no external funding for the exploration and analysis work
About the Authors
V. G. Averkova
V.I. Kulakov National Medical Scientific Centre of Obstetrics, Gynecology and Perinatal Medicine
Russian Federation
Russian Federation
117997; 4 Academician Oparin Str.; Moscow
A. E. Donnikov
V.I. Kulakov National Medical Scientific Centre of Obstetrics, Gynecology and Perinatal Medicine
Russian Federation
Russian Federation
117997; 4 Academician Oparin Str.; Moscow
References
1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L., Davies M. et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016;31(5):926–937. DOI: 10.1093/humrep/dew027
2. Panay N., Anderson R.A., Nappi R.E. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426–446. DOI: 10.1080/13697137.2020.1804547
3. Torrealday S., Kodaman P., Pal L. Premature Ovarian Insufficiency — an update on recent advances in understanding and management. F1000Res. 2017;6:2069. DOI: 10.12688/f1000research.11948.1
4. van Kasteren Y.M., Schoemaker J. Premature ovarian failure : a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum. Reprod. Update. 1999;5:483–492. DOI: 10.1093/humupd/5.5.483
5. Luisi S., Orlandini C., Regini C. et al. Premature ovarian insufficiency: from pathogenesis to clinical management. J. Endocrinol. Invest. 2015;38(6):597–603. DOI: 10.1007/s40618-014-0231-1
6. Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil. Steril. 2016;106(7):1588–1599. DOI: 10.1016/j.fertnstert.2016.09.046
7. Kawamura K. Cheng Y., Suzuki N. et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc. Natl. Acad. Sci. U S A. 2013;110(43):17474–17479. DOI: 10.1073/pnas.1312830110
8. Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil. Steril. 2013;100(5):1224–1231. DOI: 10.1016/j.fertnstert.2013.08.041
9. Grieve K.M., McLaughlin M., Dunlop C.E. et al. The controversial existence and functional potential of oogonial stem cells. Maturitas. 2015;82(3):278–281. DOI: 10.1016/j.maturitas.2015.07.017
10. Chu M.C., Rath K.M., Huie J., Taylor H.S. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum. Reprod. 2003;18:1570–1573. DOI: 10.1093/humrep/deg330
11. Fenton A.J. Premature ovarian insufficiency: Pathogenesis and management. J. Midlife Health. 2015;6(4):147–153. DOI: 10.4103/0976-7800.172292
12. Muka T., Oliver-Williams C., Kunutsor S. et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality : a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776. DOI: 10.1001/jamacardio.2016.2415
13. Podfigurna A., Stellmach A., Szeliga A. et al. Metabolic profile of patients with premature ovarian insufficiency. J. Clin. Med. 2018;7(10): E374. DOI: 10.3390/jcm7100374
14. Rahman I., Akesson A., Wolk A. Relationship between age at natural menopause and risk of heart failure. Menopause. 2015;22:12–16. DOI: 10.1097/GME.0000000000000261
15. Kuylaksizoglu M., Ipeka S., Kebapcilar L. et al. Risk factors for diabetes mellitus in women with premature ovarian insufficiency. Biol. Trace Elim. Rep. 2013;154(3):313–320. DOI: 10.1007/s12011-013-9738-0
16. Langrish J.P., Mills N.L., Bath L.E. et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension.;53(5):805–811. DOI: 10.1161/HYPERTENSIONAHA.108.126516
17. Ostberg J.E., Storry C., Donald A.E. et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabol- ism. Clin. Endocrinol. 2007;66:557–464. DOI: 10.1111/j.1365-2265.2007.02772.x
18. El Khoudary S.R. Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause : A narrative review. Maturitas. 2017;104:44–53. DOI: 10.1016/j.maturitas.2017.08.003
19. Giordano S., Hage F.G., Xing D. et al. Estrogen and cardiovascular disease: is timing everything? Am. J. Med. Sci. 2015;350(1):27–35. DOI: 10.1097/MAJ.0000000000000512
20. Maclaran K., Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond). 2015;11(2):169–182. DOI: 10.2217/whe.14.82
21. Hamoda H. The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post. Reprod. Health. 2017;23(1):22–35. DOI: 10.1177/2053369117699358
22. Sassarini J., Lumsden M.A., Critchley H.O. Sex hormone replacement in ovarian failure e new treatment concepts. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(1):105–114. DOI: 10.1016/j.beem.2014.09.010
23. Bachelot A., Nicolas C., Gricourt S. et al. Poor compliance to hormone therapy and decreased bone mineral density in women with premature ovarian insufficiency. PLoS One. 2016;11:e0164638. DOI: 10.1371/journal.pone.0164638
24. Xu X., Jones M., Mishra G.D. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum. Reprod. 2020;35:203–211. DOI: 10.1093/humrep/dez259
25. Popat V.B., Calis K.A., Kalantaridou S.N. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 2014;99(9):3418–3426. DOI: 10.1210/jc.2013-4145
26. Shah S., Nguyen H.H., Vincent A.J. Care of the adult woman with Turner syndrome. Climacteric. 2018;21(5):428–436. DOI: 10.1080/13697137.2018.1476969
27. Manolaga S.C. The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 2013;9(12):699–712. DOI: 10.1038/nrendo.2013.179
28. Burgos N., Cintron D., Latortue-Albino P. et al. Estrogen-based hormone therapy in women with primary ovarian insufficiency : a systematic review. Endocrine. 2017;58(3):413–425. DOI: 10.1007/s12020-017-1435-x
29. Cintron D., Rodriguez-Gutierrez R., Serrano V. et al. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with Turner syndrome : a systematic review and meta-analysis. Endocrine. 2017;55(2):366–375. DOI: 10.1007/s12020-016-1046-y
30. Cui X., Cui Y., Shi L. et al. A basic understanding of Turner syndrome: Incidence, complications, diagnosis, and treatment. Intractable Rare Dis. Res. 2018;7(4):223–228. DOI: 10.5582/irdr.2017.01056
31. Benetti-Pinto C.L., Ferreira V.B., Yela D.A. Long-term follow-up of bone density in women with primary ovarian insufficiency. Menopause. 2015;22(9):946–949. DOI: 10.1097/GME.0000000000000445
32. Popat V.B., Calis K.A., Kalantaridou S.N. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 2014;99(9):3418–3426. DOI: 10.1210/jc.2013-4145
33. Zuckerman-Levin N., Frolova-Bishara T., Militianu D. et al. Androgen replacement therapy in Turner syndrome: a pilot study. J. Clin. Endocrinol. Metab. 2009;94(12): 4820–4827. DOI: 10.1210/jc.2009-0514
34. Hewlett M., Mahalingaiah S. Update on primary ovarian insufficiency. Curr. Opin. Endocrinol. Diabetes Obes. 2015;22(6):483–489. DOI: 10.1097/MED.0000000000000206
35. Nappi R.E., Cucinella L., Martini E. et al. Sexuality in premature ovarian insufficiency. Climacteric. 2019;22:289–295. DOI: 10.1080/13697137.2019.1575356
36. van der Stege J.G., Groen H., van Zadelhoff S.J. et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008;15(1):23–31. DOI: 10.1097/gme.0b013e3180f6108c
37. De Almeida D.M., Benetti-Pinto C.L., Makuch M.Y. Sexual function of women with premature ovarian failure. Menopause. 2011;18(3):262–266. DOI: 10.1097/gme.0b013e3181f4318d
38. Schmidt P.J., Luff J.A., Haq N.A. et al. Depression in women with spontaneous 46,XX primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2011;96(2):E278–E287. DOI: 10.1210/jc.2010-0613
39. Liao K.L., Wood N., Conway G.S. Premature menopause and psychological well-being. J. Psychosom. Obstet. Gynaecol. 2000;21(3):167–174. DOI: 10.3109/01674820009075624
40. Mann E., Singer D., Pitkin J. et al. Psychosocial adjustment in women with premature menopause: a cross-sectional survey. Climacteric. 2012;15(5):481–489. DOI: 10.3109/13697137.2011.647841
41. Averkova V.G., Yureneva S.V. Quality of life in patients with premature ovarian insufficiency treated with hormone replacement therapy. Obstetrics and Gynecology. 2023;(5):50–58. DOI: 10.18565/aig.2023.16
42. Calik-Ksepka A., Grymowicz M., Rudnicka E. et al. Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency. Prz Menopauzalny. 2018;17(3):131–134. DOI: 10.5114/pm.2018.78558
43. Faubion S.S., Sood R., Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin. Proc. 2017;92(12):1842–1849. DOI: 10.1016/j.mayocp.2017.08.019
44. Bonetti-Pinto C.L., Giraldo P.C., Pacello P.C.C. et al. Vaginal epithelium and microflora characteristics in women with premature ovarian failure under hormone therapy compared to healthy women. Arch. Gynecol. Obstet. 2015;292:159–164. DOI: 10.1007/s00404-015-3616-2
45. Rocca W.A., Bower J.H., Maraganore D.M. et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–1083. DOI: 10.1212/01.wnl.0000276984.19542.e6
46. Bove R., Secor E., Chibnik L.B. et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014;82(3):222–229. DOI: 10.1212/WNL.0000000000000033
Review
For citations:
Averkova V.G., Donnikov A.E. Premature Ovarian Insufficiency: Long-Term Health Consequences and Hormone Replacement Therapy Strategies. Title. 2023;22(5):49-53. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-5-49-53
Views:
28
Email this article 